ordaos
  • News
  • Events
  • Team
  • Contact Us

Ordaōs in the News

We are in the news because we’re making huge strides in human-enabled, machine-driven drug design.

3/10/2025

Quercus Biosolutions emerges from stealth to disrupt crop protection with designer mini proteins

8/24/2023

Ordaōs Opens Lab Space in JLABS@NYC

8/8/2023

Ordaōs Uses AI to Generate Therapeutic Mini-Proteins

6/30/2023

AI has secured a footing in drug discovery. Where does it go from here?

6/9/2023

Ordaōs Selected to Participate in the AWS Generative AI Accelerator

3/9/2023

Can drug design replace drug discovery? Current JLABS resident Ordaos thinks so and explains how

2/22/2023

Ordaōs and FatiAbGen Partner to Optimize Therapeutics for Challenging Oncology Conditions

2/10/2023

Scrip Asks…What Does 2023 Hold For Biopharma? Part 6: Artificial Intelligence

2/6/2023

ChatGPT Is Just The 'Tip Of The Iceberg' In Content-Creating Artificial Intelligence; Get Ready For 'A Lot Of Disruption'

2/1/2023

The Generative AI Revolution is Creating The Next Phase Of Autonomous Enterprise

12/19/2022

Ordaōs Announces a Joint Development Agreement to Create Novel Therapeutics for AML

12/15/2022

Ordaōs Announces Appointment of Ziwei Liang, PhD to Role of Chief Science Officer

11/24/2022

Ordaõs Looks To Unlock The Therapeutic Promise Of Mini-Proteins

10/12/2022

Ordaōs and NonExomics Announce Research Collaboration

9/21/2022

Mini-Proteins Combine Best of Monoclonals and Small-Molecule Drugs

9/12/2022

Ordaōs/NonExomics Deal Shines Light on Novel Mini-Proteins

8/25/2022

Ordaōs Raises $5 Million in Seed to Accelerate Drug Design and Discovery

4/22/2021

Vyant Bio, Inc., Ordaōs Bio, and Cellaria, Inc. Announce Collaboration to Design and Qualify Biomarker-Specific Small Protein Therapeutics

Posters

Read abstracts and sign up to download more info

AACR 2022: Deep Learning Based Protein Therapeutics Design to Treat HER2+ CancersAACR 2022: Deep Learning Based Protein Therapeutics Design to Treat HER2+ Cancers
AET 2022: Using deep learning to discover functional antibodies for SARS-CoV-2 with picomolar binding affinityAET 2022: Using deep learning to discover functional antibodies for SARS-CoV-2 with picomolar binding affinity
PEGS 2022: Using deep learning to discover functional antibodies for SARS-CoV-2 with picomolar binding affinity PEGS 2022: Using deep learning to discover functional antibodies for SARS-CoV-2 with picomolar binding affinity
Ordaos
  • News
  • Team
  • Contact Us
  • Careers

Connect

Partner

  • Contact Us

Join

Careers

228 Park Ave S 60684,
New York, NY 10003, USA

Privacy Policy | Terms of Use